Acadian Asset Management LLC Akebia Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

  • $48.4 Billion
  • Q2 2025

A detailed history of Acadian Asset Management LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 1,350,185 shares of AKBA stock, worth $4.13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,350,185
Holding current value
$4.13 Million
% of portfolio
0.01%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025
BUY
$1.55 - $3.97 $2.09 Million - $5.36 Million
1,350,185 New
1,350,185 $4.91 Million
Q2 2024

Aug 06, 2024
SELL
$0.86 - $1.63 $1.07 Million - $2.03 Million
-1,246,372 Reduced 23.47%
4,063,383 $4.14 Million
Q1 2024

May 10, 2024
SELL
$1.27 - $2.24 $2.04 Million - $3.6 Million
-1,605,748 Reduced 23.22%
5,309,755 $9.72 Million
Q4 2023

Feb 13, 2024
SELL
$0.8 - $1.28 $246,388 - $394,220
-307,985 Reduced 4.26%
6,915,503 $8.57 Million
Q3 2023

Nov 13, 2023
SELL
$0.87 - $1.84 $206,072 - $435,831
-236,865 Reduced 3.17%
7,223,488 $8.23 Million
Q2 2023

Aug 07, 2023
SELL
$0.51 - $1.43 $11,577 - $32,461
-22,700 Reduced 0.3%
7,460,353 $6.82 Million
Q3 2022

Nov 14, 2022
BUY
$0.3 - $0.46 $43,203 - $66,244
144,010 Added 1.96%
7,483,053 $2.37 Million
Q2 2022

Aug 09, 2022
BUY
$0.32 - $0.67 $2.35 Million - $4.92 Million
7,339,043 New
7,339,043 $2.59 Million
Q3 2021

Nov 12, 2021
SELL
$2.35 - $3.88 $24,994 - $41,267
-10,636 Closed
0 $0
Q2 2021

Aug 11, 2021
BUY
$2.83 - $4.2 $24,156 - $35,851
8,536 Added 406.48%
10,636 $40,000
Q1 2021

May 11, 2021
SELL
$2.92 - $5.06 $2.44 Million - $4.22 Million
-833,985 Reduced 99.75%
2,100 $7,000
Q4 2020

Feb 11, 2021
BUY
$2.22 - $3.78 $259,224 - $441,383
116,768 Added 16.23%
836,085 $2.34 Million
Q3 2020

Nov 09, 2020
BUY
$2.39 - $13.08 $1.71 Million - $9.36 Million
715,611 Added 19309.53%
719,317 $1.81 Million
Q2 2020

Aug 12, 2020
BUY
$6.67 - $13.58 $24,719 - $50,327
3,706 New
3,706 $50,000
Q4 2018

Feb 07, 2019
SELL
$5.39 - $9.15 $396,251 - $672,671
-73,516 Closed
0 $0
Q3 2018

Oct 30, 2018
SELL
$7.44 - $10.65 $202,055 - $289,232
-27,158 Reduced 26.98%
73,516 $649,000
Q2 2018

Jul 24, 2018
SELL
$9.15 - $11.34 $1.83 Million - $2.27 Million
-199,758 Reduced 66.49%
100,674 $1.01 Million
Q1 2018

Apr 12, 2018
SELL
$9.53 - $15.68 $3.09 Million - $5.09 Million
-324,735 Reduced 51.94%
300,432 $2.86 Million
Q4 2017

Jan 18, 2018
SELL
$14.24 - $19.59 $1.47 Million - $2.02 Million
-103,062 Reduced 14.15%
625,167 $9.3 Million
Q3 2017

Oct 13, 2017
BUY
$13.06 - $19.67 $9.51 Million - $14.3 Million
728,229
728,229 $14.3 Million

Others Institutions Holding AKBA

# of Institutions
169
Shares Held
105M
Call Options Held
134K
Put Options Held
262K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $563M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email